MK-8776 (SCH 900776)

製品コードS2735

MK-8776 (SCH 900776)化学構造

分子量(MW):376.25

MK-8776 (SCH 900776)は一種の選択性的なChk1阻害剤で、無細胞試験でIC50値が3nMですが、Chk1に作用する選択性はChk2に作用する選択性より500倍が高くなります。臨床2期。

サイズ 価格(税別) 在庫  
JPY 34860.00 あり
JPY 61420.00 あり
JPY 161020.00 あり

カスタマーフィードバック(4)

  • MCF7 cells were seeded in 60 mm dishes and were pretreated with the specified inhibitor 1 h before stimulation with either vehicle or doxorubicin. Twenty-four hours after treatment, cells were collected and immunoblotted for nSMase2 and actin.

    Cell Death Dis, 2015, 6:e1947.. MK-8776 (SCH 900776) purchased from Selleck.

    (A, B) In the three TNBC cell lines, the numbers of autophagy-related spots were significantly increased in IR-alone group, and this effect was significantly suppressed by MK-8776 (IR vs MK-8776+IR: 65±23 vs 13±8, P<0.0001 in MDA-MB-231; 57±32 vs 18±7, P=0.0014 in BT-549; 43±35 vs 14±10, P=0.021 in CAL-51).

    Acta Pharmacol Sin, 2017, 38(4):513-523. MK-8776 (SCH 900776) purchased from Selleck.

  • HT29 cells were treated with 1 μM V411, 3 μM LY2603618 (LY), 3 μM MK-8776 (MK), 3 μM GNE-900 (GNE) or 0.3 μM ARRY-1A (ARRY) for 24 h. The fraction of γH2AX, pRPA32 (S4/S8), pChk1 (S317) or pChk2 (T68) positive nuclei were determined by single cell immunofluorescent imaging (n=4, mean ± SD). B. HT29 cells were treated as above for 2 or 24 h. Cell lysates were probed with the indicated antibodies by immunoblotting.

    Oncotarget, 2016, 7(51):85033-85048. MK-8776 (SCH 900776) purchased from Selleck.

    Hela cell was trypsinized and plated at 30% confluence in DMEM. 16 hours later, MK-8776 (SCH900776) was added at final concentrations of 0, 5, 10 and 25uM. Another 24 hours later, cells were harvested in RIPA with protease and phosphatase inhibitor cocktail. Total protein concentration was measured by BCA method. Lysates equivalent to 20ug total protein were subject to Western Blot, using total- CHK1, pS345-CHK1 and beta-actin (internal control) antibodies.

    MK-8776 (SCH 900776) purchased from Selleck.

製品安全説明書

Chk阻害剤の選択性比較

生物活性

製品説明 MK-8776 (SCH 900776)は一種の選択性的なChk1阻害剤で、無細胞試験でIC50値が3nMですが、Chk1に作用する選択性はChk2に作用する選択性より500倍が高くなります。臨床2期。
ターゲット
Chk1 [1]
(Cell-free assay)
CDK2 [1]
(Cell-free assay)
3 nM 0.16 μM
体外試験

SCH 900776 is a less potent inhibitor of Chk2 and CDK2 with IC50 of 1.5 μM and 0.16 μM, respectively. SCH 900776 shows no significant inhibition of cytochrome P450 human liver microsomal isoforms 1A2, 2C9, 2C19, 2D6, and 3A4. SCH 900776 induces a dose-dependent loss of DNA replication capability 24 hours after hydroxyurea exposure. SCH 900776 enhances the γ-H2AX response of hydroxyurea, 5-fluoruracil, and cytarabine. In combination with an antimetabolite, SCH 900776 induces accumulation of γ-H2AX within 2 hours, indicative of replication fork collapse and double stranded DNA breaks. Additionally, SCH 900776 suppresses accumulation of the Chk1 pS296 autophosphorylation in a dose-dependent manner. Exposure of proliferating WS1 cells to SCH 900776 is associated with rapid, dose-dependent accumulation of Chk1 pS345, indicating that cycling populations of normal cells induce Chk1 pS345 following exposure to SCH 900776 as part of a futile cycle, perhaps driven by AT-family kinases and DNA-PK.[1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U251 NIjEdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12xeVIxOC9{MECwJI5O MVmyOEBp MXLk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MorNNlQ{PTl3Mk[=
HCT115 NHm2RphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnONlAxNzJyMECgcm0> M2nleVI1KGh? Mke1[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n MVmyOFM2QTV{Nh?=
SW620 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvkO3NxOjByL{KwNFAhdk1? NX\RNppEOjRiaB?= MYLk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? Mk\3NlQ{PTl3Mk[=
IGROV-1 NF7EUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLuUIkzODBxMkCwNEBvVQ>? MmjDNlQhcA>? MUnk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MUmyOFM2QTV{Nh?=
HCT116 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DLflIxOC9{MECwJI5O NGn4XpEzPCCq MYXk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MmOwNlQ{PTl3Mk[=
MCF10A MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfodVUzODBxMkCwNEBvVQ>? NEHz[FUzPCCq NXPn[XRR\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l NHv6[ZIzPDN3OUWyOi=>
MiaPaCa-2 M2e5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSyNFAwOjByMDDuUS=> M{DBSlI1KGh? NEXsUINl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= NED2OGkzPDN3OUWyOi=>
MDA-MB-231 MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvDRmw4OjByL{KwNFAhdk1? MoTwNlQhcA>? M2Dq[oRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= NEHSOGIzPDN3OUWyOi=>
HCC2998 NEnYcHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPiSVAzODBxMkCwNEBvVQ>? NYGzbmZWOjRiaB?= MXrk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MYWyOFM2QTV{Nh?=
U87 Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCyNFAwOjByMDDuUS=> Mn;JNlQhcA>? NFzW[Wdl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= MVOyOFM2QTV{Nh?=
MDA-MB-435 NYPSSGp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXKSnkzODBxMkCwNEBvVQ>? MYOyOEBp NIH6WGNl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= M3roV|I1OzV7NUK2
SNB19 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXiyNFAwOjByMDDuUS=> NFX1flAzPCCq NGDFZoVl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= MVqyOFM2QTV{Nh?=
U20S MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TjRlIxOC9{MECwJI5O M1vMSlI1KGh? MXrk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? NVzXXmtbOjR|NUm1NlY>
A498 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2yNFAwOjByMDDuUS=> MV[yOEBp M3LiT4Rm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= MoO3NlQ{PTl3Mk[=
TK10 MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPmNlAxNzJyMECgcm0> NXvFS211OjRiaB?= MmPx[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NYXB[5NlOjR|NUm1NlY>
AsPC-1 NHjYSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWiz[G12OjByL{KwNFAhdk1? NV3ZVYU3OjRiaB?= NHvk[IFl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= Mn;5NlQ{PTl3Mk[=
H23 NECyWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XQWFUxOCCwTR?= M1:1TFI1KGh? NXixeYtoTE2VTx?= M1nCZYVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:gVG1Z NUC4NIdxOjRzMUO1OFk>
H1437 M2fk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTGeXp1PTByIH7N MYiyOEBp NF\VbGtFVVOR NGTaW4lmdmijbnPld{B1cGViY3jlcY9{\W6|aYTpfoF1cW:wIITvJHBOYA>? MnPqNlQyOTN3NEm=
H1993 NYDJc2tCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWm1NFAhdk1? MlXKNlQhcA>? MlHmSG1UVw>? NF7hOo1mdmijbnPld{B1cGViY3jlcY9{\W6|aYTpfoF1cW:wIITvJHBOYA>? Mle2NlQyOTN3NEm=
H1299 NITuU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGzOVAxKG6P NGizeYkzPCCq MnztSG1UVw>? MVvlcohidmOnczD0bIUh[2inbX;z[Y5{cXSrenH0bY9vKHSxIGDNXC=> NVPsSlRqOjRzMUO1OFk>
AsPC-1 NWfBeI1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmxNE0yODByIH7N MlvHNlQuPDiq M1vXfIVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU> MWGyN|gxPDR{Mh?=
MiaPaCa-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fmdVExNTFyMECgcm0> M3T2d|I1NTR6aB?= M2\yW4VvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU> NW[1XZhoOjN6MES0NlI>
BxPC-3 M1rjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG2NVAuOTByMDDuUS=> NInPRnczPC12OHi= MWrlcohidmOnczD0bIUh[2inbX;z[Y5{cXSrenH0bY9vKHSxIHflcYNqfGGkaX7l NGjEemszOzhyNESyNi=>
SKOV3 NXOwS|lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHqeJBEOC5|INM1US=> M33RcFgh\A>? M17HW5NmdnOrdHn6[ZMhfGinIHPlcIwhdGmwZYOgeI8h\2WvY3n0ZYJqdmYEoB?= MlTQNlM2PDh{Nkm=
OVCAR-8 M2nuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVywMlMhyrWP NH;zT5I5KGR? MVTz[Y5{cXSrenXzJJRp\SClZXzsJIxqdmW|IITvJIdmdWOrdHHibY5myqB? MmPpNlM2PDh{Nkm=
MV-4-11 NGrHWXRCeG:ydH;zbZMhSXO|YYm= NH\pSlEyODBvN{CwJI5O MUi0PEBp NXnmbm9NcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MnW2NlM2OzZ5MkG=
U937 NFnmZ3hCeG:ydH;zbZMhSXO|YYm= M4\LdFExOC15MECgcm0> NITxTXc1QCCq NIPDRVFqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 M1PxVlI{PTN4N{Kx
MOLM-13  NV75fGdvSXCxcITvd4l{KEG|c3H5 NEDSPW0yODBvN{CwJI5O MWi0PEBp MkXkbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NIfsUpYzOzV|NkeyNS=>
A2058  NUC4dY81S2WubDDWbYFjcWyrdImgRZN{[Xl? NXO4eIhCOzdwNT2zNFAhdk1? M1Wzc|czKGh? NH:3NVZFVVOR M4C5U5Jm\HWlZYOgeIhmKE2NLUG3O|UhTUN3MNMgZpkhPS2ob3zkJJRwKGGwIHH2[ZJi\2Vib3[gOFUhdk1? NV\0XpVXOjNzNEi2PFQ>
H2009 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3f2SFUxOCCwTR?= NFGxd404OiCq MULEUXNQ NGfZfoRz\XO3bITzJIlvKEdzL2OtdIhie2ViYXPjeY12dGG2aX;uJINwdWKrbnXkJJdqfGhiTVutNVc4PQ>? MnP6NlMyPDh4OES=
Su.86.86 NIrL[HZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYDv[IR{PTByIH7N NXXINGlJPzJiaB?= M3nCPGROW09? NULhNXRMemW|dXz0d{BqdiCJMT;TMZBp[XOnIHHjZ5VufWyjdHnvckBkd22kaX7l[EB4cXSqIF3LMVE4PzV? MnfiNlMyPDh4OES=
HRE M4nlcGNmdGxiVnnhZoltcXS7IFHzd4F6 MV:1NFAhdk1? M4rl[|czKGh? M4HvdmROW09? M{\lc5Jme3WudIOgbY4hTzFxUz3wbIF{\SCjY3P1cZVt[XSrb36gZ49u[mmwZXSge4l1cCCPSz2xO|c2 MX2yN|E1QDZ6NB?=
HMEC M4rPW2NmdGxiVnnhZoltcXS7IFHzd4F6 MXy1NFAhdk1? MnPDO|IhcA>? NEjJdWdFVVOR MWHy[ZN2dHS|IHnuJGcyN1NvcHjhd4Uh[WOldX31cIF1cW:wIHPvcYJqdmWmIIfpeIghVUtvMUe3OS=> Ml3UNlMyPDh4OES=
U2OS  NYfWcY4yTnWwY4Tpc44hSXO|YYm= MWiyJOK2VQ>? NUPnZZI{OC1{NDDo NXrjOnpEcW6mdXPld{BxcG:|cHjvdplt[XSrb36gc4YhS2itMTDheEB{\XKrbnWgN|Q2KGG2IHLveIgh[2:wY3XueJJifGmxboOgZZMh\WG{bImgZZMhOiCqIHHmeIVzKGGmbXnubZN1emG2aX;u M33FXFIzQTN5MUS3
U2OS  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DSSlAuOTBiwsXN Ml7xNlQwPDhiaB?= MoXabY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MW[yNlk{PzF2Nx?=
U937 NITEU5NHfW6ldHnvckBCe3OjeR?= NFWy[XMyODBvNUCwJI5O MnTwOEBpyqB? NG\ROZpl\WO{ZXHz[ZMhfGinIHP5eIFz[WKrbnWtbY5lfWOnZDDDbIsyKGG3dH;wbI9{eGixconsZZRqd25iYYSgV4VzOjl4wrDhcoQheHKndnXueJMhS2SlMkXBJIRwf26{ZXf1cIF1cW:w NWr1PG94OjJ6Nkm4Olk>
U937 NWnWfHhVTnWwY4Tpc44hSXO|YYm= NHTZd|gyODBibl2= MVi0JIjDqA>? MnHwdoV3\XK|ZYOgeIhmKGO7dHHyZYJqdmVvaX7keYNm\CCrbnjpZol1cW:wIH;mxsA{UC22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBqdnSxIFTORS=> Mk\sNlI5Pjl6Nkm=
U937 MkC2SpVv[3Srb36gRZN{[Xl? NV[zSm54OTByLUWwNEBvVQ>? MlTBOEBpyqB? NUjsdHh4cW6mdXPld{BqdmO{ZXHz[YQheGixc4Doc5J6dGG2aX;uJI9nKEh{QWi= M1P5dlIzQDZ7OE[5
HL-60 M17sRWFxd3C2b4Ppd{BCe3OjeR?= MnfKN|AwOTByL{OwNEBvVQ>? NFezXG4zPCCq MX\EUXNQ NELHdYdmdmijbnPld{BkgXSjcnHibY5mNWmwZIXj[YQh[XCxcITvd4l{ NEDRNpEzOjh4OUi2PS=>
ML-1 MoLVRZBweHSxc3nzJGF{e2G7 NE\1Wo4zPS93MD:xNFAhdk1? MUCyOEBp MXvEUXNQ NIK3U2pmdmijbnPld{BkgXSjcnHibY5mNWmwZIXj[YQh[XCxcITvd4l{ MYiyNlg3QTh4OR?=
HCT116 NUDKUmg4TnWwY4Tpc44hSXO|YYm= NXzjZoFzOSEEtV2= M1LVT|I1KGh? M1fh[IFjem:pYYTld{Bw\iClZXzsJIN6[2ynIHHydoV{fMLi MXWyNlUyODV4MB?=
U2OS Ml[wSpVv[3Srb36gRZN{[Xl? NIXGZ28yKML3TR?= NXTKUoFkOjRiaB?= M{[3ZoFjem:pYYTld{Bw\iClZXzsJIN6[2ynIHHydoV{fMLi NYfiXoRWOjJ3MUC1OlA>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Administered 30 minutes after gemcitabine, 4 mg/kg SCH 900776 is sufficient to induce the γ-H2AX biomarker while 8 mg/kg leads to enhanced tumor pharmacodynamic and regression responses relative to gemcitabine or SCH 900776 alone. Dose escalation of SCH 900776 (16 mg/kg and 32 mg/kg) induces incremental improvements in tumor response. Importantly, doses of SCH 900776 associate with robust biomarker activation and improved tumor response are not associated with enhanced toxicity of gemcitabine on hematological parameters in BALB/c mice. [1]

お薦めの試験操作(参考用のみ)

動物試験:[1]
+ 展開
  • 動物モデル: Female nude mice injected subcutaneously with A2780 or MiaPaCa2 cells
  • 製剤: Formulated in 20% hydroxypropyl β-cyclodextrin
  • 投薬量: ~50 mg/kg
  • 投与方法: Administered intraperitoneally
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 3 mg/mL (7.97 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
4% DMSO+30% propylene glycol
5 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 376.25
化学式

C15H18BrN7

CAS No. 891494-63-6
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01870596 Completed Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia National Cancer Institute (NCI) May 2013 Phase 2
NCT00907517 Terminated Myelogenous Leukemia, Acute|Leukemia, Lymphocytic, Acute|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive|Myelogenous Leukemia, Chronic, Aggressive Phase Merck Sharp & Dohme Corp. July 2009 Phase 1
NCT00779584 Completed Hodgkin Disease|Lymphoma, Non-Hodgkin|Neoplasms Merck Sharp & Dohme Corp. October 2008 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I would like to know whether your product S2735 is the optically pure R enantiomer or whether it is a racemic mix.

  • 回答:

    Our S2735 MK-8776 (SCH 900776) is R enantiomer.

Chk信号経路図

Chk Inhibitors with Unique Features

相関Chk製品

Tags: MK-8776 (SCH 900776)を買う | MK-8776 (SCH 900776) ic50 | MK-8776 (SCH 900776)供給者 | MK-8776 (SCH 900776)を購入する | MK-8776 (SCH 900776)費用 | MK-8776 (SCH 900776)生産者 | オーダーMK-8776 (SCH 900776) | MK-8776 (SCH 900776)化学構造 | MK-8776 (SCH 900776)分子量 | MK-8776 (SCH 900776)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID